Incyte Corporation

NasdaqGS:INCY Voorraadrapport

Marktkapitalisatie: US$13.8b

Incyte Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Incyte heeft een totaal eigen vermogen van $3.2B en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $5.0B en $1.8B.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsration/a
ContantUS$1.77b
AandelenUS$3.17b
Totaal verplichtingenUS$1.84b
Totaal activaUS$5.01b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Oct 31

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 19

Incyte: The Worst Has Been Avoided

Jun 16

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Jun 06
It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

May 07
We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

May 03
Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Apr 26

Incyte: A Potential GARP Superstar

Feb 27

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Feb 02
Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Oct 31
Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Knight's affiliate files for Brazilian approval of cancer drug tafasitamab

Oct 07

Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart

Sep 29

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia

Sep 15

Incyte wins approval of Pemazyre for rare blood cancer

Aug 26

Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%

Aug 02

With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case

Jul 27
With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case

Incyte Corp. Should Move Higher (Technical Analysis)

Jul 18

Incyte: Growth Drivers Are Coming

Jun 17

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $2.8B ) INCY } overtreffen de korte termijn passiva ( $1.5B ).

Langlopende schulden: De kortetermijnactiva INCY ( $2.8B ) overtreffen de langetermijnschulden ( $339.6M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: INCY is schuldenvrij.

Schuld verminderen: INCY heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 0.7% was.

Schuldendekking: INCY heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: INCY heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.


Balans


Ontdek gezonde bedrijven